A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas

A southwest oncology group study

T. D. Brown, P. Goodman, T. Fleming, J. S. Macdonald, Evan M Hersh, T. J. Braun

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Twenty-two evaluable patients with advanced adenocarcinoma of the pancreas, but without prior chemotherapy or immunotherapy, received recombinant tumor necrosis factor (rTNF). rTNF was given as an intravenous infusion over 30 min daily X 5, every 14 days, at a starting dose of 150 μg/m2/day. Toxicities included fevers/rigors, nausea/vomiting/anorexia, flu-like symptoms, hypotension, hyperglycemia, anemia, coagulopathy, hepatotoxicity, and hypertriglyceridemia. Laboratory evidence of disseminated intravascular coagulopathy occurred in 11 patients, with only 3 of these patients having clinical manifestations. Two patients suffered from pulmonary emboli. The high incidence of coagulopathy was felt to be, at least in part, disease related. No objective responses were observed with a 95% confidence interval of 0-15%.

Original languageEnglish (US)
Pages (from-to)376-378
Number of pages3
JournalJournal of Immunotherapy
Volume10
Issue number5
StatePublished - 1991

Fingerprint

Pancreas
Adenocarcinoma
Tumor Necrosis Factor-alpha
Hypertriglyceridemia
Anorexia
Embolism
Intravenous Infusions
Hyperglycemia
Immunotherapy
Hypotension
Nausea
Vomiting
Anemia
Fever
Confidence Intervals
Drug Therapy
Lung
Incidence

Keywords

  • Pancreatic adenocarcinoma
  • Recombinant tumor necrosis factor

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas : A southwest oncology group study. / Brown, T. D.; Goodman, P.; Fleming, T.; Macdonald, J. S.; Hersh, Evan M; Braun, T. J.

In: Journal of Immunotherapy, Vol. 10, No. 5, 1991, p. 376-378.

Research output: Contribution to journalArticle

Brown, T. D. ; Goodman, P. ; Fleming, T. ; Macdonald, J. S. ; Hersh, Evan M ; Braun, T. J. / A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas : A southwest oncology group study. In: Journal of Immunotherapy. 1991 ; Vol. 10, No. 5. pp. 376-378.
@article{fe885c7e8a6f4a8c93c35c4a0f958efd,
title = "A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: A southwest oncology group study",
abstract = "Twenty-two evaluable patients with advanced adenocarcinoma of the pancreas, but without prior chemotherapy or immunotherapy, received recombinant tumor necrosis factor (rTNF). rTNF was given as an intravenous infusion over 30 min daily X 5, every 14 days, at a starting dose of 150 μg/m2/day. Toxicities included fevers/rigors, nausea/vomiting/anorexia, flu-like symptoms, hypotension, hyperglycemia, anemia, coagulopathy, hepatotoxicity, and hypertriglyceridemia. Laboratory evidence of disseminated intravascular coagulopathy occurred in 11 patients, with only 3 of these patients having clinical manifestations. Two patients suffered from pulmonary emboli. The high incidence of coagulopathy was felt to be, at least in part, disease related. No objective responses were observed with a 95{\%} confidence interval of 0-15{\%}.",
keywords = "Pancreatic adenocarcinoma, Recombinant tumor necrosis factor",
author = "Brown, {T. D.} and P. Goodman and T. Fleming and Macdonald, {J. S.} and Hersh, {Evan M} and Braun, {T. J.}",
year = "1991",
language = "English (US)",
volume = "10",
pages = "376--378",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas

T2 - A southwest oncology group study

AU - Brown, T. D.

AU - Goodman, P.

AU - Fleming, T.

AU - Macdonald, J. S.

AU - Hersh, Evan M

AU - Braun, T. J.

PY - 1991

Y1 - 1991

N2 - Twenty-two evaluable patients with advanced adenocarcinoma of the pancreas, but without prior chemotherapy or immunotherapy, received recombinant tumor necrosis factor (rTNF). rTNF was given as an intravenous infusion over 30 min daily X 5, every 14 days, at a starting dose of 150 μg/m2/day. Toxicities included fevers/rigors, nausea/vomiting/anorexia, flu-like symptoms, hypotension, hyperglycemia, anemia, coagulopathy, hepatotoxicity, and hypertriglyceridemia. Laboratory evidence of disseminated intravascular coagulopathy occurred in 11 patients, with only 3 of these patients having clinical manifestations. Two patients suffered from pulmonary emboli. The high incidence of coagulopathy was felt to be, at least in part, disease related. No objective responses were observed with a 95% confidence interval of 0-15%.

AB - Twenty-two evaluable patients with advanced adenocarcinoma of the pancreas, but without prior chemotherapy or immunotherapy, received recombinant tumor necrosis factor (rTNF). rTNF was given as an intravenous infusion over 30 min daily X 5, every 14 days, at a starting dose of 150 μg/m2/day. Toxicities included fevers/rigors, nausea/vomiting/anorexia, flu-like symptoms, hypotension, hyperglycemia, anemia, coagulopathy, hepatotoxicity, and hypertriglyceridemia. Laboratory evidence of disseminated intravascular coagulopathy occurred in 11 patients, with only 3 of these patients having clinical manifestations. Two patients suffered from pulmonary emboli. The high incidence of coagulopathy was felt to be, at least in part, disease related. No objective responses were observed with a 95% confidence interval of 0-15%.

KW - Pancreatic adenocarcinoma

KW - Recombinant tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0025948022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025948022&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 376

EP - 378

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 5

ER -